NCT06053658 2026-04-14
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
14 trialsNCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT07218692 2025-10-20
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT01853644 2021-10-12
TIVO
Northwestern University
Phase 2 Completed
NCT01297244 2020-10-27
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01673386 2020-10-27
TAURUS
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT01745367 2020-10-27
BATON-BC
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00502307 2020-09-01
A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01782313 2019-09-09
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Northwestern University
Phase 2 Completed
NCT01846871 2019-01-08
Tivozanib for Recurrent Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT01972516 2017-06-05
Tivozanib As Maintenance Therapy In GYN
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01807156 2016-04-22
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Emory University
Phase 2 Terminated
NCT01478594 2015-07-08
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
AVEO Pharmaceuticals, Inc.
Phase 2 Completed
NCT01834183 2013-06-19
Tivozanib + Gemcitabine in Metastatic RCC
Dana-Farber Cancer Institute
Phase 2 Withdrawn